← Back to all trials
Recruiting
NCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction
Conditions: Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: Northside Hospital, Inc.
Location: Caitlin Guzowski Atlanta Georgia
Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Eligibility Criteria
Inclusion Criteria:
* Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
* Adequate bone marrow function to receive lymphodepleting chemotherapy
* Renal function \20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
Source: ClinicalTrials.gov (NCT05909059). StuddyBuddy aggregates publicly available trial information.
